le Nestour E, Marraoui J, Lahlou N, Roger M, de Ziegler D, Bouchard P
Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
J Clin Endocrinol Metab. 1993 Aug;77(2):439-42. doi: 10.1210/jcem.77.2.8345049.
Follicular recruitment takes place under FSH stimulation at the end of the luteal phase and the beginning of the subsequent follicular phase, the so-called luteal-follicular transition (LFT). Inhibin, a known suppressor of FSH, has been implicated in the onset of the rise in FSH levels, as the fall in its immunoreactive plasma levels after the demise of the corpus luteum has been shown to correlate negatively with the increase in FSH. To analyze the role of estradiol (E2), another inhibitor of FSH secretion in the LFT, we designed an experimental paradigm to dissociate the physiological falls in inhibin and E2. This was achieved by extending the duration of luteal plasma E2 levels with transdermal E2 treatment. Untreated ovulatory cycles in seven healthy female volunteers, aged 28-38 yr, were compared with E2-treated cycles in the same subjects, with treatment starting on the 10th day after the LH surge and continuing through the 4th day of the following menses [either 0.2 mg (n = 6; G1) or 0.1 mg (n = 6; G2) E2 daily]. Blood samples were obtained daily from the LH surge until the 11th day of the next cycle. Immunoreactive plasma inhibin levels reached a nadir on day 2 of menses regardless of whether women received E2. Plasma E2 (mean +/- SEM) levels remained within the normal luteal range (220 +/- 51 to 635 +/- 279 pmol/L) until the end of the treatment period in G2 (range, 253 +/- 40 to 382 +/- 62 pmol/L), but not in G1 (range, 598 +/- 195 to 1835 +/- 1259 pmol/L). However, the onset of the FSH rise was clearly delayed, from a mean of 2 days before menstruation in the controls to day 4 of the cycle in G1 and G2. Peak plasma FSH levels were attained within 6 days in the controls and within 2 or 3 days in both treatment periods. Our data suggest that it is the decrease in plasma E2 rather than inhibin that is the triggering signal for the LFT rise in plasma FSH. The exact roles of inhibin and other gonadal proteins (e.g. activins) in follicular recruitment remain to be determined.
卵泡募集在黄体期末和随后卵泡期开始时,即在所谓的黄体 - 卵泡转换期(LFT),在促卵泡激素(FSH)刺激下发生。抑制素是一种已知的FSH抑制剂,已被认为与FSH水平升高的起始有关,因为黄体退化后其免疫反应性血浆水平的下降已被证明与FSH的增加呈负相关。为了分析雌二醇(E2)在LFT中作为FSH分泌的另一种抑制剂的作用,我们设计了一个实验范式来区分抑制素和E2的生理性下降。这是通过经皮E2治疗延长黄体期血浆E2水平的持续时间来实现的。将7名年龄在28 - 38岁的健康女性志愿者的未治疗排卵周期与同一受试者的E2治疗周期进行比较,治疗从促黄体生成素(LH)峰后第10天开始,持续到下一次月经的第4天[每天分别给予0.2 mg(n = 6;G1组)或0.1 mg(n = 6;G2组)E2]。从LH峰开始每天采集血样,直至下一个周期的第11天。无论女性是否接受E2治疗,免疫反应性血浆抑制素水平在月经第2天达到最低点。在G2组中,直到治疗期结束,血浆E2(平均值±标准误)水平仍保持在正常黄体期范围内(220±51至635±279 pmol/L)(范围为253±40至382±62 pmol/L),但在G1组中并非如此(范围为598±195至1835±1259 pmol/L)。然而,FSH升高的起始明显延迟,从对照组月经前平均2天延迟到G1组和G2组周期的第4天。对照组在6天内达到血浆FSH峰值水平,两个治疗组在2或3天内达到。我们的数据表明,血浆FSH在LFT中升高的触发信号是血浆E2的下降而非抑制素。抑制素和其他性腺蛋白(如激活素)在卵泡募集中的确切作用仍有待确定。